| 1 |
Alexandraki KI, Angelousi A, Chatzellis E, Chrisoulidou A, Kalogeris N, Kanakis G, Savvidis C, Vassiliadi D, Spyroglou A, Kostopoulos G, Markussis V, Toulis K, Tsagarakis S, Kaltsas GA. The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis. J Pers Med 2023;13. [PMID: 36836538 DOI: 10.3390/jpm13020304] [Reference Citation Analysis]
|
| 2 |
Panzuto F, Ricci C, Rinzivillo M, Magi L, Marasco M, Lamberti G, Casadei R, Campana D. The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Clin Med 2022;11. [PMID: 36294448 DOI: 10.3390/jcm11206127] [Reference Citation Analysis]
|
| 3 |
Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
|
| 4 |
Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J. High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now? Curr Treat Options Oncol 2022. [PMID: 35501552 DOI: 10.1007/s11864-022-00983-z] [Reference Citation Analysis]
|
| 5 |
Merola E, Michielan A, Rozzanigo U, Erini M, Sferrazza S, Marcucci S, Sartori C, Trentin C, de Pretis G, Chierichetti F. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World J Gastrointest Surg 2022; 14(2): 78-106 [DOI: 10.4240/wjgs.v14.i2.78] [Reference Citation Analysis]
|
| 6 |
Sharma N, Sharma D. An Overview of Pancreatic Neuroendocrine Tumors. Challenges in Pancreatic Cancer 2021. [DOI: 10.5772/intechopen.96259] [Reference Citation Analysis]
|
| 7 |
Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer 2021;157:403-14. [PMID: 34597974 DOI: 10.1016/j.ejca.2021.06.056] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 9 |
Sesti F, La Salvia A, Grinzato C, Mazzilli R, Faggiano A. L’approccio con analoghi della somatostatina nelle neoplasie neuroendocrine associate a sindromi neoplastiche multi-endocrine ereditarie. L'Endocrinologo 2021;22:423-428. [DOI: 10.1007/s40619-021-00952-y] [Reference Citation Analysis]
|
| 10 |
Ronde EM, Heidsma CM, Eskes AM, Schopman JE, Nieveen van Dijkum EJM. Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Eur J Cancer Care (Engl) 2021;30:e13504. [PMID: 34462979 DOI: 10.1111/ecc.13504] [Reference Citation Analysis]
|
| 11 |
Chandrasekharan C. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:293-316. [PMID: 32151362 DOI: 10.1016/j.soc.2019.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 12 |
Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Garcia-Alvarez A, Hernando Cubero J, Capdevila J. Drug Development in Neuroendocrine Tumors: What Is on the Horizon? Curr Treat Options Oncol 2021;22:43. [PMID: 33786683 DOI: 10.1007/s11864-021-00834-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 14 |
Shamsi BH, Chatoo M, Xu XK, Xu X, Chen XQ. Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System. Front Endocrinol (Lausanne) 2021;12:652363. [PMID: 33796080 DOI: 10.3389/fendo.2021.652363] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 15 |
Falconi M, Fazio N, Ferone D, Versari A. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Expert Opin Pharmacother 2020;21:2317-24. [PMID: 32990061 DOI: 10.1080/14656566.2020.1810237] [Reference Citation Analysis]
|
| 16 |
Brighi N, Panzuto F, Modica R, Gelsomino F, Albertelli M, Pusceddu S, Massironi S, Lamberti G, Rinzivillo M, Faggiano A, Spallanzani A, Ferone D, Prinzi N, Rossi RE, Annibale B, Colao AM, Campana D. Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. Oncologist 2020;25:259-65. [PMID: 32162819 DOI: 10.1634/theoncologist.2019-0403] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 17 |
Lamberti G, Faggiano A, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. J Clin Endocrinol Metab 2020;105:dgz035. [PMID: 31545377 DOI: 10.1210/clinem/dgz035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 18 |
Gabrielsen J, Girone G, Bennett B, Jung A. Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors. J Adv Pract Oncol 2019;10:646-59. [PMID: 33391850 DOI: 10.6004/jadpro.2019.10.7.2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 19 |
Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 20 |
Kendi AT, Halfdanarson TR, Packard A, Dundar A, Subramaniam RM. Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors. AJR Am J Roentgenol. 2019;213:309-317. [PMID: 31039017 DOI: 10.2214/ajr.19.21123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 21 |
de Herder WW. When and How to Use Somatostatin Analogues. Endocrinology and Metabolism Clinics of North America 2018;47:549-55. [DOI: 10.1016/j.ecl.2018.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 22 |
Singh S, Chan DL. Small Bowel Neuroendocrine Tumors: Big Advances in the Land of Small Tumors. J Oncol Pract 2018;14:485-6. [PMID: 30096275 DOI: 10.1200/JOP.18.00392] [Reference Citation Analysis]
|
| 23 |
Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal 2018; 6(2): 9-20 [DOI: 10.13105/wjma.v6.i2.9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 24 |
Zatelli MC, Guadagno E, Messina E, Lo Calzo F, Faggiano A, Colao A; NIKE Group. Open issues on G3 neuroendocrine neoplasms: back to the future. Endocr Relat Cancer 2018;25:R375-84. [PMID: 29669844 DOI: 10.1530/ERC-17-0507] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 25 |
Ore AS, Barrows CE, Solis-Velasco M, Shaker J, Moser AJ. Robotic enucleation of benign pancreatic tumors. J Vis Surg 2017;3:151. [PMID: 29302427 DOI: 10.21037/jovs.2017.08.15] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 26 |
Mazziotti G, Mosca A, Frara S, Vitale G, Giustina A. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opin Pharmacother. 2017;18:1679-1689. [PMID: 29067877 DOI: 10.1080/14656566.2017.1391217] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
